826 related articles for article (PubMed ID: 19254704)
1. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
[TBL] [Abstract][Full Text] [Related]
2. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy.
Marcaccini AM; Novaes AB; Meschiari CA; Souza SL; Palioto DB; Sorgi CA; Faccioli LH; Tanus-Santos JE; Gerlach RF
Clin Chim Acta; 2009 Nov; 409(1-2):117-22. PubMed ID: 19751716
[TBL] [Abstract][Full Text] [Related]
3. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
[TBL] [Abstract][Full Text] [Related]
4. Different circulating metalloproteinases profiles in women with migraine with and without aura.
Martins-Oliveira A; Speciali JG; Dach F; Marcaccini AM; Gonçalves FM; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2009 Oct; 408(1-2):60-4. PubMed ID: 19627981
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of plasma MMP-8, MMP-9 and TIMP-1 identifies candidate cardiometabolic risk marker in metabolic syndrome: results from double-blinded nested case-control study.
Hoseini SM; Kalantari A; Afarideh M; Noshad S; Behdadnia A; Nakhjavani M; Esteghamati A
Metabolism; 2015 Apr; 64(4):527-38. PubMed ID: 25633268
[TBL] [Abstract][Full Text] [Related]
6. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
[TBL] [Abstract][Full Text] [Related]
7. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension.
Palei AC; Sandrim VC; Cavalli RC; Tanus-Santos JE
Clin Biochem; 2008 Jul; 41(10-11):875-80. PubMed ID: 18477480
[TBL] [Abstract][Full Text] [Related]
8. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
[TBL] [Abstract][Full Text] [Related]
9. Increased levels of atherosclerosis markers in salt-sensitive hypertension.
Larrousse M; Bragulat E; Segarra M; Sierra C; Coca A; de La Sierra A
Am J Hypertens; 2006 Jan; 19(1):87-93. PubMed ID: 16461197
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases (MMP-8, MMP-9) and the tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2) in patients with fungal keratitis.
Rohini G; Murugeswari P; Prajna NV; Lalitha P; Muthukkaruppan V
Cornea; 2007 Feb; 26(2):207-11. PubMed ID: 17251814
[TBL] [Abstract][Full Text] [Related]
11. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
13. Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease.
Cicero AF; Derosa G; Manca M; Bove M; Borghi C; Gaddi AV
Endothelium; 2007; 14(4-5):193-8. PubMed ID: 17922335
[TBL] [Abstract][Full Text] [Related]
14. Increase in the ratio of matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 in saliva from patients with primary Sjögren's syndrome.
Asatsuma M; Ito S; Watanabe M; Takeishi H; Nomura S; Wada Y; Nakano M; Gejyo F; Igarashi A
Clin Chim Acta; 2004 Jul; 345(1-2):99-104. PubMed ID: 15193983
[TBL] [Abstract][Full Text] [Related]
15. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
17. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.
Pawlak K; Pawlak D; Mysliwiec M
Cytokine; 2005 Jul; 31(1):18-24. PubMed ID: 15896974
[TBL] [Abstract][Full Text] [Related]
18. Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios.
Pérez P; Kwon YJ; Alliende C; Leyton L; Aguilera S; Molina C; Labra C; Julio M; Leyton C; González MJ
Arthritis Rheum; 2005 Sep; 52(9):2751-60. PubMed ID: 16142742
[TBL] [Abstract][Full Text] [Related]
19. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
20. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]